PharmaLive: Medarex to Present at the Thomas Weisel Partners Healthcare Conference
September 3rd, 2008 | by admin |
PRINCETON, N.J., September 02, 2008 /PRNewswire-FirstCall/ — Medarex, Inc. announced today that it is scheduled to present at the Thomas Weisel Partners Healthcare Conference at 9:10 a.m. Eastern Time on Thursday, September 4, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at
www.medarex.com. An archived edition of the presentation will be available following the event.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its Web site at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, orNichol Harber, Corporate Communications (media), +1-609-430-2880, ext.2214, both of Medarex, Inc.
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
Ticker Symbol: (NASDAQ-NMS:MEDX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Stumble it!
